Sinopharm Group Co. Ltd.

1099

CNE100000FN7

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 03:18:18 2024-04-26 am EDT			5-day change	1st Jan Change
21.4 ^HKD	-1.61%		+7.65%	+4.65%

Apr. 16	Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	MT
Apr. 10	Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	MT

Sinopharm Group Co., Ltd. Announces Resignation of Dai Kun as A Non-Executive Director and A Member of the Nomination Committee of the Board

April 29, 2020 at 04:36 am EDT

The board of directors of Sinopharm Group Co. Ltd. announced that on 29 April 2020, due to job change, Ms. Dai Kun tendered her resignation as a non-executive director of the Company and a member of the nomination committee of the Board with immediate effect.

Latest news about Sinopharm Group Co. Ltd.

Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	Apr. 16	MT
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	Apr. 10	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	Mar. 27	MT
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue	Mar. 24	MT
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024	Mar. 24	CI
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 24	CI
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings	Mar. 21	MT
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%	Mar. 21	MT
US Inflation, Light News Flow Churns Asian Stock Markets	Mar. 13	MT
Sinopharm Group Co. Ltd. Announces Change of Registered Address	Mar. 12	CI
Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy	Mar. 11	MT
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer	Feb. 22	MT
China stocks extend gains led by coal, AI; HK shares up	Feb. 22	RE
Hong Kong Stocks Hover Near Two-Month Highs Amid Mixed Corporate Earnings	Feb. 22	MT
China stocks jump with AI shares leading on Nvidia forecast; HK shares flat	Feb. 21	RE
Sinopharm offers to take China-TCM private in nearly $3 bln deal	Feb. 21	RE
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	Feb. 20	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	Feb. 20	MT
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	Jan. 03	MT
Sinopharm to Renew Financial Services Deal with Affiliate	Dec. 28	MT
Hutchmed China renews deals with "substantial" shareholders	Dec. 21	AN
Wenzhou Kangning Hospital Inks Sale, Lease Back Deal With Sinopharm Holding	Dec. 20	MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets	Dec. 08	MT
Interest Rates, Earnings, FX Roil Asian Stock Markets	Nov. 24	MT
Linklogis to Offload Entire 19.6% Stake in Pharma Supply Chain Financing Associate	Nov. 23	MT

Chart Sinopharm Group Co. Ltd.

Duration

Period

More charts

Company Profile

Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Sinopharm Group Co. Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.13 CNY

Average target price

25.06 CNY

Spread / Average Target

+24.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
SINOPHARM GROUP CO. LTD.	+4.65%	8.67B
MCKESSON CORPORATION	+16.62%	70.95B
CARDINAL HEALTH, INC.	+2.99%	25.25B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.46%	8.16B
HUADONG MEDICINE CO., LTD	-21.01%	7.91B
H. LUNDBECK A/S	+0.61%	4.51B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B
EBOS GROUP LIMITED	-0.14%	4.07B
GALENICA AG	-3.64%	3.84B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+21.70%	3.63B

Pharmaceuticals Wholesale